Elsevier

The Lancet

Volume 357, Issue 9262, 7 April 2001, Pages 1069-1075
The Lancet

Articles
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

https://doi.org/10.1016/S0140-6736(00)04258-6Get rights and content

Summary

Background

Liver biopsy is thought mandatory for management of patients with hepatitis C virus (HCV) infection, especially for staging fibrosis. We aimed, in our prospective study, to assess the predictive value of a combination of basic serum biochemical markers for diagnosis of clinically significant fibrosis (including early stages).

Methods

We assessed liver-biopsy patients with detectable HCV by PCR, for eligibility, and took a blood sample on the day of the procedure. The analysis was done in a first-year period for 205 patients and then tested in a second period on 134 patients. We devised a fibrosis index that included the most informative markers (combined with age and sex) for the first-year group. 11 serum markers were assessed as well as fibrosis stage: FO=no fibrosis and F1=portal fibrosis; and for clinically significant fibrosis, F2=few septa, F3=many septa, and F4=cirrhosis. Statistical analysis was by logistic regression, neural connection, and receiver-operating characteristic (ROC) curves.

Findings

First-year and second-year patient-group characteristics and biochemical markers did not differ. The overall frequency of clinically significant fibrosis was 40% (138 patients). The most informative markers were: α2 macroglobulin, α2 globulin (or haptoglobin), γ globulin, apolipoprotein A1, γ glutamyltranspeptidase, and total bilirubin. The areas (SD) under the ROC curves for the first-year (0·836 [0·430]) and second-year groups (0·870 [0·340]) did not differ (p=0·44). With the best index, a high negative predictive value (100% certainty of absence of F2, F3, or F4) was obtained for scores ranging from zero to 0·10 (12% [41] of all patients), and high positive predictive value (>90% certainty of presence of F2, F3, or F4) for scores ranging from 0·60 to 1·00 (34% [115] of all patients).

Interpretation

A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection.

Introduction

Liver biopsy is thought mandatory for management of patients infected by hepatitis C virus (HCV), particularly to stage fibrosis.1, 2 However, after biopsy 30% of patients feel pain, 0·3% have severe complications, and 0·03% die.3, 4 Several markers have substantial predictive values for diagnosis of cirrhosis,4, 5, 6, 7, 8, 9, 10 but none are available for diagnosis of earlier stages—eg, with few septa (the start of bridging fibrosis). No prospective studies have been done in a large population infected only by HCV. We aimed to prospectively assess the predictive value of a combination of basic serum biochemical markers for the diagnosis of clinically significant fibrosis (ranging from a few septa to cirrhosis) and necroinflammatory activity (necrosis and inflammation). If markers with high positive or negative predictive values of important fibrosis can be obtained, fewer liver biopsies would need to be done and thus the cost and risk of liver biopsy would be lessened.3, 4

Section snippets

Patients

From August, 1997, to March, 2000, all liver-biopsy patients who gave informed consent and with detectable HCV by PCR were assessed for eligibility and had a blood sample taken on the day of biopsy. Patients belonged to a single centre cohort, Cohorte Hépatite C Pitié-Salpêtrière (DOSVIRC). This cohort included all patients with HCV infection (defined by a positive serological test by at least a second-generation ELISA) attending the liver and gastrointestinal unit of Pitié-Salpêtriére

Participants

We assessed 422 patients with chronic HCV infection for eligibility (figure 1). We excluded 45 because of: HIV coinfection (37), hepatitis B virus coinfection (seven), and transplantation (one). We could not stage fibrosis in 30 of the remaining 377 patients, and at least one of the 11 markers was missing in eight, which left 339 included patients. Patient characteristics and biochemical markers did not differ between first-year and second-year samples (table 1). The overall frequency of

Discussion

Our results show that a combination of five or six basic biochemical markers can have high positive or negative predictive value for diagnosis of clinically significant fibrosis, even at the early stage of a few septa. The most informative markers were, in decreasing rank: α2 macroglobulin, haptoglobin, GGT, γ globulin, total bilirubin, and apolipoprotein A1.

α2 globulin is mainly composed α2 macroglobulin nad haptoglobin. Fibrosis was associated with an increase of α2 macroglobulin and a

References (32)

  • GuillenMI et al.

    The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes

    Hepatology

    (1996)
  • PoynardT et al.

    A simple biological index for detection of alcoholic liver disease in drinkers

    Gastroenterology

    (1991)
  • PoynardT et al.

    Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

    Lancet

    (1998)
  • European Association for the Study of the Liver

    Consensus statement. EASL International Consensus Conference on Hepatitis C

    J Hepatol

    (1999)
  • PoynardT et al.

    Fibrosis in patients with chronic hepatitis C: detection and significance

    Semin Liver Dis

    (2000)
  • PoynardT et al.

    Appropriateness of liver biopsy

    Can J Gastroenterol

    (2000)
  • Cited by (0)

    View full text